natgillin/translations-raw huggingface dataset:
The pack contains 4 different packages for the first 4 weeks of treatment, one package for each week.
Paket vsebuje 4 različne pakiranja za prve 4 tedne zdravljenja – po eno pakiranje za vsak teden.
The pack contains one vial of powder and one pre-filled syringe with solvent that must be prepared for subcutaneous injection.
Zloženka vsebuje eno vialo s praškom in eno napolnjeno brizgo z vehiklom, ki ju je treba pripraviti za subkutano injekcijo.
The pack contains two vials of powder and two pre-filled syringes with solvent that must be prepared for subcutaneous injection.
Zloženka vsebuje dve viali s praškom in dve napolnjeni brizgi z vehiklom, ki ju je treba pripraviti za subkutano injekcijo.
The pack has a special device for the patient to stick the old patch before discarding.
Paket vsebuje posebno pripravo, na katero lahko nalepite stari obliž, preden ga odvržete.
The pack sizes of 5 and 10 are only available as multipacks comprising of 5 or 10 packs, each containing 1 bottle.
10 plastenk.V pakiranjih po 5 in 10 plastenk je vsaka plastenka posebej pakirana v zunanjo ovojnino.
The pack sizes of 56 x1, 98 x1 and 490 film-coated tablets are presented in unit dose blister.
V škatlah s 56 x 1, 98 x 1 in 490 filmsko obloženimi tabletami se tablete nahajajo v pretisnih omotih za enkratni odmerek.
The pack will also include information about the risks of this medicine for patients.
Izobraževalno gradivo bo vključevalo tudi informacije o tveganjih tega zdravila za bolnike.
The pack will also include information on the registry the company will set up to collect data on babies born to women treated with Gilenya, as well as a patient reminder card with key safety information for patients.
Gradivo bo prav tako vključevalo informacije o registru, ki ga bo družba vzpostavila za zbiranje podatkov o dojenčkih, ki so se rodili ženskam, zdravljenim z zdravilom Gilenya, ter opozorilno kartico za bolnike s ključnimi informacijami o varnosti zdravila.
The pack will remind them of how Tasigna should be used safely in patients.
Informativni paket jim bo v pomoč pri tem, kako zdravilo Tasigna varno uporabljati pri bolnikih.
The package leaflet
Navodilo za uporabo.
The package leaflet is updated accordingly.
Navodilo za uporabo zdravila je ustrezno posodobljeno.
The package leaflet should be provided to the patient each time Benlysta is administered (see section 4.4).
Vsakemu bolniku je treba vsakokrat, ko prejme zdravilo Benlysta, dati navodilo za uporabo tega zdravila (glejte poglavje 4.4).
The Package Leaflet should be taken to the doctor.
K zdravniku je treba prinesti Navodilo za uporabo zdravila.
The package leaflet should be updated accordingly.
Tudi navodilo za uporabo je treba ustrezno posodobiti.
The package leaflet should be updated accordingly.
Ustrezno je treba posodobiti navodilo za uporabo.
The package must be checked before use and the activity measured using a dose calibrator.
Pred uporabo je treba pregledati ovojnino in s kalibratorjem odmerka izmeriti aktivnost.
The package must be checked before use and the activity measured using an activimeter.
Pred uporabo je treba pregledati embalažo in z merilnikom aktivnosti izmeriti aktivnost.
The package must be sent to a qualified laboratory for analysis.
Zavoj je treba poslati v usposobljen laboratorij, kjer ga bodo analizirali.
The package will be opened by your nurse and the infusion bags will be stored in a refrigerator until infusion.
Pakiranje bo odprla medicinska sestra in bo infuzijske vrečke shanila v hladilnik za čas do infundiranja.
The packages are marked with ‘week 1 (2, 3 or 4)’.
Pakiranja so označena ‘1. (2., 3. ali 4.) teden’.
The packages are marked with “Week 1 (2, 3 or 4)”.
Pakiranja so označena z nalepko “1. (2., 3. ali 4.) teden”.
The packaging of this medicinal product contains natural rubber latex which may cause allergic reactions (see section 6.5).
Ovojnina tega zdravila vsebuje gumo iz naravnega lateksa, ki lahko povzroči alergijske reakcije (glejte poglavje 6.5).
The packs with 14, 28, 56, 84 and 98 tablets contain blisters with abbreviations for days of the week printed on the blister (MON, TUE, WED, THU, FRI, SAT, SUN).
Pakiranja s 14, 28, 56, 84 in 98 tabletami vsebujejo pretisne omote, na katerih so natisnjene okrajšave za dneve v tednu (PON, TOR, SRE, ČET, PET, SOB, NED).
The packs without blister are without needle safety guard.
Pakiranja brez pretisnega omota nimajo varnostne zaščite za iglo.
The paediatric dose should not exceed the 500 mg/200 mg dose.
Odmerek za otroke ne sme biti večji od 500 mg/200 mg.
The paediatric patient received
Pediatrični bolniki so prejemali po
The paediatric patients received 4 mg/kg monthly intramuscular dose of fulvestrant.
Pediatrični bolniki so mesečno prejemali fulvestrant v intramuskularnem odmerku 4 mg/kg.
The paediatric patients were aged 1 to 8 years and received 4 mg/kg monthly intramuscular dose of fulvestrant.
Pediatrični bolniki so bili stari od 1 do 8 let in so mesečno prejemali fulvestrant v intramuskularnem odmerku 4 mg/kg.
The paediatric population is defined as those persons aged between 0 and 18 years.
Pediatrična populacija se smatra kot obdobje storasti med 0 in 18 let.
The PAH can be:
PAH je lahko:
The pain may feel like it is moving through to your back or shoulder; these symptoms are uncommon and may indicate pancreas or bile duct system problems (i.e. inflammation of the pancreas or spasm of the sphincter of Oddi);
Čutite lahko, da se bolečina premika v hrbet in rame; ti simptomi so občasni in lahko kažejo na težave s trebušno slinavko ali žolčevodom (tj. vnetje trebušne slinavke ali spazem Oddijevega sfinktra);
The pain may happen with or without you being sick (vomiting).
Bolečine lahko spremlja bruhanje ali pa tudi ne.
The pain was transient and subsided without requiring any therapy.
Bolečina je bila prehodna in je popustila brez zdravljenja.
The panel of induced cytokines varies with the cell’s tissue origin.
Skupina induciranih citokinov se razlikuje glede na izvor celičnega tkiva.
The paraffin layer must not come into contact with the area to be treated to avoid covering the eschar, thus isolating the eschar from direct contact with NexoBrid.
Parafinska plast ne sme priti v stik s predelom, ki ga želite zdraviti, da ne prekrije eshar in prepreči, da bi prišle v neposredni stik z zdravilom NexoBrid.
The parent compound is widely distributed in the tissues with the highest concentrations found in the lungs, bile, intestinal mucosa, spleen, kidney and liver.
Izhodna spojina se dobro porazdeli po različnih tkivih in doseže najvišje koncentracije v pljučih, žolču, črevesni sluznici, vranici, ledvicah in jetrih.
The parent substance is predominantly metabolised to 5-carboxy-pirfenidone, and the pharmacokinetics of this metabolite is altered in subjects with moderate to severe renal impairment.
Izhodiščna spojina se v glavnem presnovi v 5-karboksi-pirfenidon, farmakokinetika tega presnovka pa se pri osebah z zmerno do hudo okvaro ledvic spremeni.
The partial patient subset of data available for CNA30021 is tabulated below, but must be interpreted with caution.
Podatki delne podskupine bolnikov, ki so na voljo za študijo CNA30021, so prikazani v spodnji preglednici, vendar jih je treba tolmačiti previdno.
The Partners PrEP clinical study (CO-US-104-0380) evaluated Truvada, tenofovir disoproxil 245 mg (as fumarate), or placebo in 4,758 HIV-uninfected subjects from Kenya or Uganda in serodiscordant heterosexual couples.
Klinična študija Partners PrEP (CO-US-104-0380) je ocenjevala zdravilo Truvada, dizoproksiltenofovirat 245 mg (v obliki fumarata) ali placebo pri 4.758 s HIV neokuženih osebah iz Kenije ali Ugande, ki so bili v serološko neskladnem heteroseksualnem partnerstvu.
The parts of the Praluent pen are shown in this picture.
Slika prikazuje dele injekcijskega peresnika zdravila Praluent.
The parts of the Praluent syringe are shown in this picture.
Slika prikazuje dele injekcijske brizge zdravila Praluent.
The patch can be used in everyday situations, including bathing and during hot weather.
Obliž je mogoče uporabljati v vsakdanjih situacijah, tudi med kopanjem in v vročem vremenu.
The patch is applied to dry, clean skin on the lower abdomen (the tummy below the waist).
Obliž se namesti na suho in čisto kožo na spodnji del trebuha (pod pasom).
The patch is designed to remain in place during these times.
Obliž je oblikovan tako, da v takih primerih ostane na mestu.
The patch is designed to stay in place during these types of activities.
Obliž je oblikovan tako, da ostane na mestu tudi v času takšnih aktivnosti.
The patch must be firmly applied to the buttock, abdomen (tummy), upper arm or upper back, but not on the breast, or on skin that is red, irritated or cut.
Obliž je treba trdno pritrditi na zadnjico, abdomen (trebuh), nadlaket ali zgornji del hrbta, ne sme se pa ga namestiti na prsi ali na pordelo, vzdraženo ali poškodovano kožo.
The patch should be applied at approximately the same time every day.
Obliž je treba namestiti vsak dan ob približno istem času.
The patch should be applied to clean, dry, intact healthy skin on the abdomen, thigh, hip, flank, shoulder, or upper arm.
Obliž namestimo na čisto, suho, nepoškodovano zdravo kožo na trebuhu, stegnih, kolkih, bokih, ramah ali nadlahteh.
The patch should be applied to dry, intact skin on the abdomen, hip, or buttock immediately after removal from the protective sachet.
Po odstranitvi zaščitne vrečke transdermalni obliž takoj namestimo na suho, nepoškodovano kožo na trebuhu, bokih ali zadnjici.
The patch should be pressed down firmly for at least 30 seconds using the palm of the hand until the edges stick well.
Obliž je treba z dlanjo čvrsto pritiskati na kožo najmanj 30 sekund, dokler se robovi dobro ne prilepijo.
The patch should be pressed down firmly with the palm of the hand for about 20 to 30 seconds, so that it sticks well.
Obliž 20 do 30 sekund trdno pritiskamo z dlanjo, da se dobro prilepi.
The patch should be replaced by a new one after 24 hours.
Obliž je treba po 24 urah zamenjati z novim.
The patch should not be cut into pieces.
Obliža se ne sme rezati na manjše dele.
The patch should not be exposed to any external heat sources (e.g. excessive sunlight, saunas, solarium) for long periods of time.
Obliža se ne sme izpostavljati zunanjim virom toplote (na primer prekomernemu sončenju, savni, solariju) za daljši čas.
The patch-free interval must not be longer than seven days; otherwise, additional non-hormonal contraceptive methods must be used, such as condoms.
Interval brez uporabe obliža ne sme biti daljši od sedem dni, v nasprotnem primeru je treba sočasno uporabljati še nehormonsko kontracepcijsko sredstvo, kot so kondomi.
The patch-free interval starts on day 22 and lasts for seven days.
Interval brez uporabe obliža se začne na 22. dan in traja sedem dni.
The pathophysiology of VOD is multifactorial and complex.
Patofiziologija VOB vključuje več dejavnikov in je kompleksna.
The patient (including caregivers) educational material should contain:
Izobraževalno gradivo za bolnike (vključno z negovalci) mora vsebovati:
The Patient Alert Card
brošuro za bolnike, opozorilno kartico za bolnike.
The Patient Alert Card for MabThera in non-oncology indications should contain the following key elements:
Opozorilna kartica za bolnika z neonkološko indikacijo mora vsebovati naslednje ključne vsebine:
The patient alert card shall contain the following key elements:
Opozorilna kartica za bolnika bo obsegala naslednje ključne elemente:
The patient alert card shall contain the following key messages:
Opozorilna kartica za bolnika mora vsebovati sledeča ključna sporočila:
The patient alert card should be given to every patient.
Zdravnik mora vsakemu bolniku izročiti kartico z opozorili za bolnika.
The Patient alert card should contain the following key safety messages:
Opozorilna kartica za bolnika mora vsebovati naslednja ključna sporočila o varnosti:
The Patient Alert Card, shall contain the following key elements:
Kartica za bolnike mora vsebovati naslednje ključne elemente:
The patient alert card, which is to be given to patients using Flixabi.
da obstaja opozorilna kartica za bolnike, ki jo morajo dati vsakemu bolniku, ki mu predpišejo zdravilo Flixabi.
The patient alert card, which is to be given to patients using Remicade.
da obstaja opozorilna kartica za bolnike, ki jo morajo dati vsakemu bolniku, ki mu predpišejo zdravilo Remicade.
The Patient Alert Card.
Kartico za bolnike.
The Patient Alert Card:
Opozorilna kartica za bolnika:
The patient brochure shall include the following key elements:
Brošura za bolnike mora vsebovati naslednje ključne elemente:
The patient can breathe normally while the vaccine is being administered – there is no need to actively inhale or sniff.
Bolnik lahko med uporabo cepiva diha normalno – ni potrebe za aktivno inhaliranje ali vdihavanje skozi nosnice.
The patient can breathe normally while the vaccine is being administered – there is no need to actively inhale or sniff.
Bolnik lahko med uporabo cepiva diha normalno – ni potrebe za aktivno inhaliranje ali vdihavanje skozi nosnici.
The patient can breathe normally while the vaccine is being administered – there is no need to actively inhale or sniff.
Oseba lahko med dajanjem cepiva normalno diha – ni potrebe za aktivno inhaliranje ali vdihavanje skozi nosnici.
The Patient Card informs patients of the risk of severe hepatic injury, and the possible symptoms, so that they are aware of situations in which they should contact a physician in a timely manner.
Kartica za bolnika bolnika seznani s tveganji za hude poškodbe jeter in možnimi simptomi, da se zaveda situacij, v katerih se mora pravočasno obrniti na zdravnika.
The Patient Card is designed to enable the physician to present patient-friendly information about Zinbryta to a patient at the time Zinbryta is prescribed.
Opozorilna kartica za bolnika omogoča, da zdravnik bolniku razumljivo predstavi informacije o zdravilu Zinbryta, ko mu je le-to predpisano.
The patient card should include an area where patients can record the date and dose of every treatment by Ruconest
opozorilna kartica za bolnika mora vsebovati prostor, kjer lahko bolnik zabeleži datum in odmerek vsakega zdravljenja z zdravilom;
The patient carrying this card is treated with Ranexa for symptomatic angina pectoris.
Bolnik, ki ima to kartico, jemlje zdravilo Ranexa za simptomatsko zdravljenje angine pektoris.
The patient complies with the conditions of the Pregnancy Prevention Programme, including confirmation that she has an adequate level of understanding
bolnica upošteva vse pogoje programa za preprečevanje nosečnosti, vključno s potrditvijo, da jih ustrezno razume, bolnica potrdi navedene pogoje.
The patient complies with the conditions of the Pregnancy Prevention Programme, including confirmation that she has an adequate level of understanding
bolnica upošteva vse pogoje programa za preprečevanje nosečnosti, vključno s potrditvijo, da jih ustrezno razume; bolnica potrdi navedene pogoje.
The patient complies with the conditions of the Thalidomide Celgene Pregnancy Prevention Programme
Bolnik/bolnica ravna v skladu s pogoji programa Thalidomide Celgene za preprečevanje nosečnosti.
The patient confirms that he (she) understand the aforementioned conditions.
Bolnik/bolnica potrdi, da razume zgoraj navedene pogoje.
The patient data should be documented using the provided data sheet.
Bolnikovi podatki se morajo zabeležiti v priloženi formular.
The patient did not experience any adverse reactions.
Neželenih učinkov pri tej bolnici ni bilo.
The patient first receives a loading dose of 80 mg under medical supervision.
Bolnik najprej prejme začetni odmerek 80 mg pod zdravniškim nadzorom.
The patient had received400 mg memantine orally.
Peroralno je dobil 400 mg memantina.
The Patient Information Brochure and Patient Alert Card shall contain the following key elements:
Brošura za bolnike in opozorilna kartica morata vsebovati naslednje ključne elemente:
The patient information guide, including the following key elements:
Vodnik informacij za bolnike, vključno z naslednjimi ključnimi točkami:
The Patient information leaflet
navodila za uporabo
The Patient Information Leaflet
Navodilo za uporabo za bolnike
The Patient Information Leaflet
Navodilo za uporabo,
The Patient Information Leaflet
Navodilo za uporabo.
The patient information pack should be provided in both the form of a patient information booklet and an audio-CD that contain following key elements:
Komplet informacij za bolnika mora biti na voljo v obliki knjižice in avdio-CD, ki vsebujejo naslednja ključna sporočila:
The patient information pack should contain the following key elements:
Informacije za bolnika morajo vsebovati:
The Patient Information Pack should contain the following key elements:
Izobraževalno gradivo za bolnike mora vključevati naslednje glavne vsebine:
The patient information pack should contain:
Paket informacij za bolnike mora vsebovati:
The patient information should contain the following key elements:
Informacije za bolnika morajo vključevati naslednje ključne elemente o:
The patient information should contain the following key elements:
Informacije za bolnika morajo vsebovati naslednje ključne elemente:
The patient is recommended to have coitus on the day of, and on the day following, hCG administration.
Bolnici svetujemo, da ima spolni odnos na sam dan in dan po tistem, ko je dobila hCG.
The patient is recommended to have coitus on the day of, and the day after, Ovitrelle injection.
Bolnici svetujemo, da ima spolni odnos na dan, ko dobi injekcijo zdravila Ovitrelle, in dan potem.
The patient is recommended to have coitus on the day of, and the day following, hCG administration.
Bolnici se priporoča spolni odnos na isti dan, ko je prejela hCG in naslednji dan.
The patient is recommended to have coitus on the day of, and the day following, hCG administration.
Bolnici se priporoča spolni odnos na isti dan, ko je prejela hCG, in naslednji dan.
The patient may notice a taste when using Budesonide/Formoterol Teva due to the lactose excipient.
Ob uporabi zdravila Budezonid/formoterol Teva bo bolnik morda zaznal okus zaradi pomožne snovi laktoze.
The patient may notice a taste when using Budesonide/Formoterol Teva Pharma B.V. due to the lactose excipient.
Ob uporabi zdravila Budezonid/formoterol Teva Pharma B.V. bo bolnik morda zaznal okus zaradi pomožne snovi laktoze.
The patient must always check if he has enough insulin for the dose.
Bolnik naj preveri, ali ima dovolj insulina za odmerek.
The patient must always check if he has enough insulin for the dose.
Bolnik naj preverite, ali ima dovolj insulina za odmerek.
The patient must always check if he has enough insulin for the dose.
Preverite, ali imate dovolj insulina za odmerek.
The patient must always have a spare OptiSet available in case the OptiSet is lost or damaged.
Bolnik mora imeti vedno na zalogi rezerven OptiSet, če injekcijski peresnik izgubi ali se ta poškoduje.
The patient must always have a spare OptiSet available in case the OptiSet is lost or damaged.
Bolnik mora imeti vedno na zalogi rezerven OptiSet, če injekcijski peresnik izgubiali se ta poškoduje.
The patient must always have a spare OptiSet available in case the OptiSet is lost or damaged.
Vedno imejte na zalogi rezerven OptiSet, če injekcijski peresnik izgubite ali se poškoduje.
The patient must always have a spare SoloStar available in case the SoloStar is lost or damaged.
Vedno imejte na zalogi rezerven SoloStar, če injekcijski peresnik izgubite ali se poškoduje.
The patient must always have a spare SoloStar available in case the SoloStar is lost or damaged.
Vedno naj ima na zalogi rezervni SoloStar, če injekcijski peresnik izgubi ali ga poškoduje.
The patient must be advised that if there is any delay in onset of menses or any otherreason to suspect pregnancy, they must notify the physician immediately for pregnancy testing, and if positive, the physician and patient must discuss the risk to the pregnancy.
Če se pojavi zamuda menstruacije ali obstaja kakšen drug razlog za sum, da je bolnica zanosila, mora o tem takoj obvestiti zdravnika in se z njim dogovoriti za nosečnostni test; če je nosečnostni test pozitiven, se morata zdravnik in bolnica pogovoriti o tveganjih v nosečnosti.
The patient must check if the selected dose is fully loaded.
Bolnik naj preveri, ali je izbrani odmerek povsem napolnjen.
The patient must check if the selected dose is fully loaded.
Preverite, ali je izbrani odmerek povsem napolnjen.
The patient must continue to breathe through the straw while removing it from the breath bag, and then immediately seal the breath bag with its stopper.
Neprekinjeno izdihujte, medtem pa bo zdravstveno osebje izvleklo slamico iz dihalne vrečke in dihalno vrečko takoj zaprlo z ustreznim zamaškom.
The patient must continue to breathe through the straw while removing it from the breath sample container, and then immediately seal the breath sample container with its stopper.
Neprekinjeno izdihujte, medtem pa bo zdravstveno osebje izvleklo slamico iz vsebnika za vzorec dihanja in epruveto takoj zaprlo z ustreznim zamaškom.
The patient must continue to breathe through the straw while removing it from the sample tube, and then immediately seal the tube with its stopper.
Neprekinjeno izdihujte, medtem pa bo zdravstveno osebje izvleklo slamico iz epruvete in epruveto takoj zaprlo z ustreznim zamaškom.
The patient must have fasted for over 6 hours, preferably overnight.
Bolnik se mora prej postiti vsaj 6 ur, najbolje čez noč.
The patient or a caregiver will be instructed in infusion techniques, the keeping of a treatment diary and measures to be taken in case of severe adverse reactions.
Bolnik ali skrbnik naj bosta poučena o tehnikah infundiranja, vodenju dnevnika zdravljenja in ukrepih, ki naj se izvedejo pri resnih neželenih učinkih.
The patient or caregiver and the doctor should decide together who will administer the Ilaris injections.
Bolnik oziroma skrbnik naj se skupaj z zdravnikom odloči, kdo bo bolniku injiciral zdravilo
The patient or caregiver can inject Omnitrope themselves, after training by a doctor or a nurse.
Bolnik ali negovalec lahko injicirata zdravilo Omnitrope sama, potem ko ju zdravnik ali medicinska sestra za to ustrezno usposobita.
The patient or caregiver can inject Somavert, after being trained by a doctor or a nurse.
Bolnik ali negovalec lahko zdravilo injicirata sama, potem ko sta ju za to usposobila zdravnik ali medicinska sestra.
The patient or caregiver can inject Valtropin after training by a doctor or a nurse.
Bolnik ali negovalec lahko zdravilo Valtropin vbrizgata sama, če ju medicinska sestra ali zdravnik za to ustrezno usposobita.
The patient or carer can give the injection after appropriate training.
Zdravilo lahko po ustreznem usposabljanju injicira bolnik ali njegov negovalec.
The patient or their partner may carry out the injection if they have been properly instructed.
Bolnica ali njen partner lahko po ustreznem usposabljanju injiciranje opravita sama.
The patient population included 19.7% women and 29.2% patients ≥65 years.
Populacijo bolnikov je sestavljalo 19,7 % žensk in 29,2 % bolnikov v starosti ≥65 let.
The patient receives four doses in total, with three weeks between each dose.
Bolnik prejme skupno štiri odmerke s tritedenskim premorom med odmerki.
The patient reminder card should contain the following key elements:
Bolnikova opomnilna kartica mora vsebovati naslednje ključne elemente:
The patient response rate was evaluated using the AIDS Clinical Trials Group (ACTG) criteria for lesion response in KS.
Stopnjo odziva pri bolnikih so analiziraliz merili za odziv lezij pri KS Skupine kliničnih študij za AIDS (ACTG).
The patient safety card and the need to carry it on their person and tell any treating healthcare professional that they are being treated with eculizumab.
opozorilno kartico za bolnika in potrebo po tem, da jo bolnik ves čas nosi s seboj ter opozori vsakega zdravstvenega delavca, ki sodeluje pri zdravljenju, da se zdravi z ekulizumabom;
The patient should also receive dexamethasone (a steroid) to help control some of the medicine’s side effects.
Bolnik mora prejeti tudi deksametazon (steroid), ki pomagajo pri nadzoru nekaterih neželenih učinkov.